A dosage effect is also suggested by the previous preliminary observation of movement disorders in heterozygous EPG5 variant carriers in a small number of families, and the suggestion of EPG5 variants as a modifying factor in Alzheimer's disease and amyotrophic lateral sclerosis.7, 28, 29. Here, EPG5 is linked to early-onset autosomal dominant Alzheimer disease.